文献速递骨软组织肉瘤与黑色素瘤

儿童青少年及青年滑膜肉瘤:COG ARST0332研究解读

Synovial Sarcoma in Children, Adolescents, and Young Adults: A Report From the Children's Oncology Group ARST0332 Study.
PubMed 文献 · J Clin Oncol · 2021-10-08

ARST0332研究按风险分层治疗30岁以下滑膜肉瘤患者,低危仅手术或放疗,中危化疗加放疗,高危新辅助化放疗后手术。138例可评估患者中,中位随访6.8年,5年无事件生存率低危82%、中危70%、高危8%,总生存率分别为98%、89%、13%。非转移患者预后优于历史对照且放疗使用更少、剂量更低,转移患者结局仍差。

要点

  • 风险分层治疗使非转移滑膜肉瘤获得良好预后,且减少放疗使用。
  • 转移性滑膜肉瘤5年总生存率仅13%,亟需新疗法。
  • 除风险分组定义特征外,年龄、性别、部位等未改善风险分层。

核心结论

  • 基于风险的治疗策略在非转移性滑膜肉瘤中较历史对照产生有利结局,且放疗使用更少、剂量更低。
  • 转移性滑膜肉瘤结局仍不理想,迫切需要新治疗。

研究设计与样本

  • 儿童肿瘤协作组(COG)ARST0332研究,纳入新诊断、年龄<30岁的滑膜肉瘤患者。
  • 根据疾病特征分配至四个治疗臂:A手术仅、B 55.8 Gy放疗、C异环磷酰胺+多柔比星化疗+55.8 Gy放疗、D新辅助化疗+45 Gy放疗后手术及按切缘追加放疗后辅助化疗。
  • A和B臂为非转移低危,C和D臂无转移为中危,有转移为高危;146例入组,138例可评估(低危46、中危71、高危21)。

主要发现

  • 肿瘤特征:80%位于肢体、70%>5 cm、70%高级别、62%侵袭性、95%深部、15%转移。
  • 治疗臂分布:A 29.7%、B 3.6%、C 16.7%、D 50%。
  • 中位随访6.8年,5年无事件生存率低危82%、中危70%、高危8%。
  • 5年总生存率低危98%、中危89%、高危13%。
  • 无毒性死亡,发生4例意外4级不良事件。

关键数值与推荐

  • 低危(A/B臂)5年无事件生存率82%,总生存率98%。
  • 中危(C/D臂无转移)5年无事件生存率70%,总生存率89%。
  • 高危(转移)5年无事件生存率8%,总生存率13%。
  • 放疗剂量:B臂和C臂55.8 Gy,D臂新辅助45 Gy后按切缘追加。

临床怎么用

  • 对非转移性滑膜肉瘤可按风险分层选择手术、放疗或化疗联合放疗,低危可限制治疗。
  • 中危患者可从新辅助化放疗及手术联合辅助化疗中获益。
  • 转移性滑膜肉瘤预后极差,应优先考虑临床试验和新药治疗。

局限性

  • 非随机分层治疗,与历史对照比较可能存在偏倚。
  • 高危转移患者样本量较小(21例)。
  • 中位随访6.8年,长期结局仍需进一步观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Synovial sarcoma (SS) is the second most common malignant soft tissue tumor in children. ARST0332 evaluated a risk-based treatment strategy for young patients with soft tissue sarcoma designed to limit therapy for low-risk (LR) disease and to test neoadjuvant chemoradiotherapy for unresected higher-risk disease. METHODS: Newly diagnosed patients with SS age < 30 years were assigned to four treatment arms based on disease features: A (surgery only), B (55.8 Gy radiotherapy [RT]), C (ifosfamide and doxorubicin [ID] chemotherapy plus 55.8 Gy RT), and D (neoadjuvant ID and 45 Gy RT, then surgery and RT boost based on margins followed by adjuvant ID). Patients treated in Arms A and B were considered LR, arms C and D without metastases as intermediate-risk (IR), and those with metastases as high-risk (HR). RESULTS: Of the 146 patients with SS enrolled, 138 were eligible and evaluable: LR (46), IR (71), and HR (21). Tumors were 80% extremity, 70% > 5 cm, 70% high-grade, 62% invasive, 95% deep, and 15% metastatic. Treatment was on arm A (29.7%), B (3.6%), C (16.7%), and D (50%). There were no toxic deaths and four unexpected grade 4 adverse events. By risk group, at a median follow-up of 6.8 years, estimated 5-year event-free survival was LR 82%, IR 70%, and HR 8%, and overall survival was LR 98%, IR 89%, and HR 13%. After accounting for the features that defined risk category, none of the other patient or disease characteristics (age, sex, tumor site, tumor invasiveness, and depth) improved the risk stratification model. CONCLUSION: The risk-based treatment strategy used in ARST0332 produced favorable outcomes in patients with nonmetastatic SS relative to historical controls despite using RT less frequently and at lower doses. The outcome for metastatic SS remains unsatisfactory and new therapies are urgently needed.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Venkatramani R, Xue W, Randall RL, et al. Synovial Sarcoma in Children, Adolescents, and Young Adults: A Report From the Children's Oncology Group ARST0332 Study. J Clin Oncol. 2021. PMID: 34623899. doi:10.1200/JCO.21.01628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。